Northwest Biotherapeutics Inc (NWBO) stock
NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
$0.16−0.00 (-0.88%)
Close on Oct 19, 2026Market cap $254.79MP/E –Yield –
Northwest Biotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Northwest Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$50.33M. For fiscal 2025 it was -$59.91M. The highest annual figure on record is -$15.35M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$59.91M | – |
| FY2024 | Dec 31, 2024 | -$66.51M | – |
| FY2023 | Dec 31, 2023 | -$55.51M | – |
| FY2022 | Dec 31, 2022 | -$67.18M | – |
| FY2021 | Dec 31, 2021 | -$52.70M | – |
| FY2020 | Dec 31, 2020 | -$86.61M | – |
| FY2019 | Dec 31, 2019 | -$27.98M | – |
| FY2018 | Dec 31, 2018 | -$41.48M | – |
| FY2017 | Dec 31, 2017 | -$54.68M | – |
| FY2016 | Dec 31, 2016 | -$79.27M | – |
| FY2015 | Dec 31, 2015 | -$126.28M | – |
| FY2014 | Dec 31, 2014 | -$101.14M | – |
| FY2013 | Dec 31, 2013 | -$55.47M | – |
| FY2012 | Dec 31, 2012 | -$43.83M | – |
| FY2011 | Dec 31, 2011 | -$26.79M | – |
| FY2010 | Dec 31, 2010 | -$15.35M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.50M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.32M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.78M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.50M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.46M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.58M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.96M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.18M | – |
| Q3 FY2022 | Sep 30, 2022 | -$15.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.10M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.29M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.05M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.36M | – |
| Q3 FY2020 | Sep 30, 2020 | -$47.88M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.54M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.83M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.73M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.59M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.64M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.77M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.99M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.32M | – |
| Q2 FY2018 | Jun 30, 2018 | -$20.35M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.82M | – |
| Q4 FY2017 | Dec 31, 2017 | -$17.98M | – |
| Q4 FY2016 | Dec 31, 2016 | -$21.25M | – |
| Q3 FY2016 | Sep 30, 2016 | -$25.52M | – |
| Q2 FY2016 | Jun 30, 2016 | -$15.02M | – |
| Q1 FY2016 | Mar 31, 2016 | -$17.48M | – |
| Q4 FY2015 | Dec 31, 2015 | -$51.39M | – |
See a number that looks wrong?